AMAG Pharmaceuticals Inc

Most Recent

  • uploads///Amazon
    Tech & Comm Services

    Amazon Dealt with Regulators Last Week

    Amazon, Apple, Google, and Facebook have been fending off probes about corporate governance policy for managing user data.

    By Shankar Iyer
  • uploads///Spectrum net loss
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Makena Auto Injector Is a Key Asset for Antares Pharma in 2018

    In H1 2018, Antares Pharma (ATRS) reported revenues of $6.7 million from its Makena product.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Antares Pharma Could Report Solid Revenue Growth in Fiscal 2018

    In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%.

    By Margaret Patrick
  • uploads///syringe __
    Company & Industry Overviews

    Analyst Ratings for AMAG Pharmaceuticals and Peers in February

    Of the 12 analysts covering AMAG Pharmaceuticals, three have given the stock a “buy” or higher rating, and nine have given it a “hold.”

    By Kenneth Smith
  • uploads///Amag key products
    Company & Industry Overviews

    Label Expansion of Ferahame Bodes Well for AMAG Pharmaceuticals

    AMAG’s revenues from Ferahame grew at a higher pace to $26 million in 3Q17 from $22.2 million in 3Q16.

    By Kenneth Smith
  • uploads///amag collaborations
    Company & Industry Overviews

    A Look at AMAG Pharmaceuticals’ Collaborations

    AMAG Pharmaceuticals’ business strategy includes the expansion of its portfolio through licensing and acquisitions of additional pharmaceutical products.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    How Does Incyte’s Valuation Compare to Its Peers?

    In this series, we’ll look at the performance of Incyte’s existing products and other factors that are driving the company’s revenues and valuation.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Incyte’s Valuation Compare to Peers?

    Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.

    By Mike Benson
  • uploads///US High Yield Bond Fund Flows
    Company & Industry Overviews

    Outflows Resume for High Yield Bond Funds

    Investor flows in high yield bond funds returned to negative territory last week, after having seen inflows in the previous week.

    By David Ashworth
  • uploads///US Leveraged Loans Flows
    Company & Industry Overviews

    Leveraged Loan Fund Outflows Reach Highest Level Yet in 2015

    According to Lipper, leveraged loan funds saw outflows for the week ended August 19, making it the fourth such successive week. The quantum of outflows was $754 million, the highest so far in 2015.

    By David Ashworth
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.